



DARE TO HUMANCARE

A purpose-driven, innovative medicines company

Luzsana Biotechnology™, a wholly owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), is a global development and commercialization biotechnology organization committed to delivering innovative medicines that are available, accessible, and affordable to patients around the world.

Unique co-development and commercialization model

Through a strategic plan with Hengrui Pharma, Luzsana will co-develop innovative medicines in areas of high unmet medical need with the objective of commercializing in North America, Europe, and Japan.

Luzsana will partner with Hengrui Pharma to assess and hand-select assets from its robust pipeline for global co-development and commercialization, without needing to make significant investments in high-risk, early discovery and manufacturing.

Luzsana and Hengrui Pharma



50+ years of proven excellence in research & development (R&D) innovation, manufacturing, as well as sales of innovative medicines



World-class pipeline of **250+** clinical studies across multiple therapeutic areas



16 R&D centers



8 high-quality manufacturing facilities




Global clinical trial networks across the United States, Europe, Japan, and China offer Luzsana a potential path to increase speed to market via this co-development model.

Luzsana will leverage the discovery and manufacturing capabilities of Hengrui Pharma with the goal of reducing co-development costs, creating opportunities for Luzsana to reinvest those savings into proven access solutions to overcome barriers and improve the availability, accessibility, and affordability of innovative medicines at a local level.

Innovative medicines

Luzsana has initially selected 11 high-potential oncology and non-oncology programs that span all stages of development, from preclinical to Phase 3 for co-development. These programs address areas of high unmet needs, some with first-in-class or best-in-class potential. The company intends to further diversify its pipeline over time.



Proven solutions to improve access and address the healthcare paradox

There are more innovative medicines than ever being developed around the globe, yet many people can't access these medicines.¹ This is referred to as “the healthcare paradox.”



From 2010 to 2020, the number of new molecular entity approvals in oncology by the FDA increased by **150%**²



The World Health Organization lists **25 essential** cancer medications¹



Only 10% of countries worldwide have made all 25 available to patients¹

To address the healthcare paradox, Luzsana will reinvest co-development cost savings into proven market-access solutions tailored to local regions and healthcare ecosystems, in order to overcome barriers and improve the availability, accessibility, and affordability of innovative medicines.

References:

1. Cortes J, Perez-García JM, Llombart-Cussac A, et al. Enhancing global access to cancer medicines. *CA Cancer J Clin.* 2020;70(2):105-124. 2. Data on file. Luzsana Biotechnology, Inc., 2022.